爱尔康收购全球首款且唯一干性黄斑病变光疗技术

医疗器械创新网07-08

爱尔康宣布将收购眼科光疗创新企业LumiThera及其用于治疗早中期干性年龄相关性黄斑变性（AMD）的PBM光生物调节治疗设备---VALEDA。VALEDA是目前唯一被证实能有效改善早中期干性AMD患者基线视力的治疗装置。爱尔康本次收购主要是收购LumiThera的VALEDA，而LumiThera其它业务AdaptDx、Nova/Diopsys将被剥离，继续由LumiThera股东的新公司运营...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2549851424?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-08 16:31","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2549851424","market":"us","top_or_hot":-1,"title":"爱尔康收购全球首款且唯一干性黄斑病变光疗技术","media":"医疗器械创新网","content":"<div>\n<p>爱尔康宣布将收购眼科光疗创新企业LumiThera及其用于治疗早中期干性年龄相关性黄斑变性（AMD）的PBM光生物调节治疗设备---VALEDA。VALEDA是目前唯一被证实能有效改善早中期干性AMD患者基线视力的治疗装置。爱尔康本次收购主要是收购LumiThera的VALEDA，而LumiThera其它业务AdaptDx、Nova/Diopsys将被剥离，继续由LumiThera股东的新公司运营...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708163516a69cbc53&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>爱尔康收购全球首款且唯一干性黄斑病变光疗技术</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n爱尔康收购全球首款且唯一干性黄斑病变光疗技术\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-08 16:31 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708163516a69cbc53&s=b><strong>医疗器械创新网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>爱尔康宣布将收购眼科光疗创新企业LumiThera及其用于治疗早中期干性年龄相关性黄斑变性（AMD）的PBM光生物调节治疗设备---VALEDA。VALEDA是目前唯一被证实能有效改善早中期干性AMD患者基线视力的治疗装置。爱尔康本次收购主要是收购LumiThera的VALEDA，而LumiThera其它业务AdaptDx、Nova/Diopsys将被剥离，继续由LumiThera股东的新公司运营...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708163516a69cbc53&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2264538146.SGD","symbol_name":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708163516a69cbc53&s=b","article_id":"2549851424","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708163516a69cbc53&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2549851424","pubTimestamp":1751963465,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"爱尔康宣布将收购眼科光疗创新企业LumiThera及其用于治疗早中期干性年龄相关性黄斑变性的PBM光生物调节治疗设备---VALEDA。VALEDA是目前唯一被证实能有效改善早中期干性AMD患者基线视力的治疗装置。爱尔康本次收购主要是收购LumiThera的VALEDA，而LumiThera其它业务AdaptDx、Nova/Diopsys将被剥离，继续由LumiThera股东的新公司运营。本次收购预计今年第三季度完成。在LIGHTSITE 3试验中，Valeda达到了主要终点，且被证明是安全有效的。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","BK4198":"医疗保健用品","LU0889565833.HKD":"FRANKLIN TECHNOLOGY \"A\" (HKD) ACC","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LU0056508442.USD":"贝莱德世界科技基金A2","BK4139":"生物科技","LU1303367103.USD":"摩根大通多经理另类基金 A (acc)","BK4529":"IDC概念","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU1316542783.SGD":"Janus Henderson Horizon Global Technology Leaders A2 SGD","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","LU0823421333.USD":"BNP PARIBAS DISRUPTIVE TECHNOLOGY \"C\" (USD) ACC","BK4575":"芯片概念","LU2098885051.SGD":"JPMorgan Funds - Multi-Manager Alternatives A (acc) SGD","BK4566":"资本集团","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","LU1852331112.SGD":"Blackrock World Technology Fund A2 SGD-H","LU2458330169.SGD":"FRANKLIN SHARIAH TECHNOLOGY \"A\" (SGD) ACC","LU1880398554.USD":"AMUNDI FUNDS GLOBAL EQUITY \"A2\" (USD) INC","LU1880398471.USD":"AMUNDI FUNDS GLOBAL EQUITY \"A2\" (USD) ACC","LU2360106780.USD":"BGF WORLD TECHNOLOGY \"A4\" (USD) INC","PBM":"Psyence Biomedical Ltd","BK4512":"苹果概念","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU2250418816.HKD":"BGF WORLD TECHNOLOGY \"A\" (HKD) ACC","LU1951198990.SGD":"Natixis Thematics AI & Robotics Fund H-R/A SGD-H","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","IE00B5949003.HKD":"JANUS HENDERSON GLOBAL TECHNOLOGY AND INNOVATION \"A\" (HKD) ACC","BK4588":"碎股","LU1951200564.SGD":"Natixis Thematics AI & Robotics Fund R/A SGD","BK4614":"Manus概念股","BK4605":"半导体精选","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","LU0082616367.USD":"摩根大通美国科技A（dist）","IE0009356076.USD":"JANUS HENDERSON GLOBAL TECHNOLOGY AND INNOVATION \"A2\" (USD) ACC","LU1803068979.SGD":"FTIF - Franklin Technology A (acc) SGD-H1","LU0081259029.USD":"UBS (LUX) EQUITY FUND - TECH OPPORTUNITY \"P\" (USD) ACC","LU1923623000.USD":"Natixis Thematics AI & Robotics Fund R/A USD","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","IE00BMPRXR70.SGD":"Neuberger Berman 5G Connectivity A Acc SGD-H","BK4573":"虚拟现实","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","BK4532":"文艺复兴科技持仓","BK4543":"AI","ALC":"Alcon Inc"},"translate_title":"Alcon acquires the world's first and only phototherapy technology for dry maculopathy","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALC":0.9,"PBM":1},"content_text":"爱尔康宣布将收购眼科光疗创新企业LumiThera及其用于治疗早中期干性年龄相关性黄斑变性（AMD）的PBM光生物调节治疗设备---VALEDA。VALEDA是目前唯一被证实能有效改善早中期干性AMD患者基线视力的治疗装置。爱尔康本次收购主要是收购LumiThera的VALEDA，而LumiThera其它业务AdaptDx、Nova/Diopsys将被剥离，继续由LumiThera股东的新公司运营。本次收购预计今年第三季度完成。Valeda光传递系统Valeda光传输系统是一种使用光生物调节（PBM）技术的非侵入性治疗设备，其使用不同波长的光来刺激视网膜细胞的活动。视网膜是人体能量需求最大的器官之一，其能量需求超过大脑，视网膜细胞也是人体内对能量依赖程度最高的细胞之一。线粒体在能量代谢中发挥核心作用，线粒体功能障碍会对视网膜健康产生直接和破坏性的影响，特定波长的PBM可以直接刺激线粒体能量的产生。Valeda使用三种不同的发光二极管来刺激细胞的功能，可提高代谢并激活细胞再生，590nm的波长用于减少血管内皮生长因子和细胞沉积；660nm的波长提高了细胞色素C氧化酶的氧结合，并具有消炎作用；850nm的波长可以刺激代谢活动，具有消炎作用并减少细胞死亡。Valeda作用机制：这种疗法通过使用特定波长的光来刺激视网膜细胞，激活线粒体呼吸链组分，促进细胞增殖和保护，从而改善视力。PBM通过靶向组织中的光感受器吸收光子来发挥作用，产生的次级细胞效应包括能量生成的增加以及信号传导模式的改变，例如活性氧（ROS）、一氧化氮（NO）和细胞内钙的变化，从而促进细胞增殖和细胞保护。PBM通过激活线粒体呼吸链组分，特别是细胞色素C氧化酶（Cox）来发挥作用。Cox是线粒体电子传递链的末端酶，对ATP的产生至关重要。在暴露于红外光或近红外光下时，Cox能以氧化或还原的形式被激活，从而提高线粒体膜电位，促进ATP的合成。# 临床试验进展LIGHTSITE IIIB 为一项前瞻性、开放标签临床试验，纳入对象为完成LIGHTSITE III研究的患者。试验设计为13个月内每4个月接受一轮PBM治疗，每轮包含9次治疗，每次约4分钟/眼。在LIGHTSITE 3试验中，Valeda达到了主要终点，且被证明是安全有效的。研究显示，在24个月内，Valeda能使最佳矫正视力(BCVA)改善超过5个字母，相当于视力表上提升一行。LIGHTSITE 3B扩展试验的结果将关键性试验的2年视力益处延长至4.5年，并且展现出良好的安全性。数据显示在接受PBM治疗的患者中，超过60%在完成两阶段试验后，最佳矫正视力较基线提升5个字母以上，约等于提升视力表上的一行；地图样萎缩（GA）新发比例在PBM组为1.1%，对照组为10%，具有统计学显著性（p=0.025）；治疗耐受性良好，未观察到严重不良事件，患者依从性高。研究者指出，在前期治疗结束后20个月的无干预期内，部分视力改善仍得以维持，而在重新启动治疗后，患者BCVA再次上升，提示PBM疗法具有一定的可重复性和延续性。▲文章来源：MedTF、眼未来▲转载请标注以上来源声明：本文仅作信息传递之目的，仅供参考。本文不对投资及治疗构成任何建议，请谨慎甄别。如涉及作品内容、版权和其它问题，为保障双方权益，请与我们联系，我们将立即处理。如有平台转载本篇文章，须自行对该篇文章负责，医疗器械创新网不对转载引起的二次传播负责。往/期/回/顾GE重大人事变动，新总裁“五一”到任！巨头混战！谁能拿下BD2000亿“大蛋糕”？卷哭同行，联影再包揽1.13亿大标！","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,merge","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2549851424","isCrawlerRequest":true}